Amgen Inc. (NASDAQ:AMGN) has been assigned an average recommendation of “Buy” from the twenty-seven brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation, twelve have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $186.10.

A number of brokerages recently issued reports on AMGN. UBS AG reiterated a “neutral” rating and issued a $174.00 target price (down from $175.00) on shares of Amgen in a report on Monday, May 22nd. Mizuho set a $195.00 price objective on Amgen and gave the company a “buy” rating in a research note on Saturday, May 6th. BMO Capital Markets restated a “buy” rating and set a $198.00 price objective (down from $200.00) on shares of Amgen in a research note on Monday, May 22nd. Cowen and Company restated an “outperform” rating and set a $209.00 price objective on shares of Amgen in a research note on Wednesday, April 19th. Finally, Morgan Stanley raised their price objective on Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, June 13th.

In related news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the sale, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. TrimTabs Asset Management LLC raised its position in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC raised its position in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. raised its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the last quarter. American Beacon Advisors Inc. bought a new position in Amgen during the first quarter worth $106,000. Finally, Nelson Roberts Investment Advisors LLC bought a new position in Amgen during the first quarter worth $121,000. 79.12% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Amgen Inc. (AMGN) Receives Consensus Recommendation of “Buy” from Brokerages” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/15/amgen-inc-amgn-receives-consensus-recommendation-of-buy-from-brokerages.html.

Shares of Amgen (NASDAQ:AMGN) traded down 0.28% during mid-day trading on Tuesday, hitting $170.04. 1,956,277 shares of the stock were exchanged. The stock’s 50 day moving average price is $174.35 and its 200-day moving average price is $167.93. The stock has a market capitalization of $124.07 billion, a P/E ratio of 15.49 and a beta of 1.35. Amgen has a 12-month low of $133.64 and a 12-month high of $184.21.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period last year, the business earned $2.84 EPS. Amgen’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts expect that Amgen will post $12.57 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be issued a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.71%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is currently 41.93%.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.